CN114028434A - A composition for treating diabetes - Google Patents
A composition for treating diabetes Download PDFInfo
- Publication number
- CN114028434A CN114028434A CN202110012077.0A CN202110012077A CN114028434A CN 114028434 A CN114028434 A CN 114028434A CN 202110012077 A CN202110012077 A CN 202110012077A CN 114028434 A CN114028434 A CN 114028434A
- Authority
- CN
- China
- Prior art keywords
- percent
- composition
- diabetes
- selenium
- chromium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 81
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 57
- FZAQROFXYZPAKI-UHFFFAOYSA-N anthracene-2-sulfonyl chloride Chemical compound C1=CC=CC2=CC3=CC(S(=O)(=O)Cl)=CC=C3C=C21 FZAQROFXYZPAKI-UHFFFAOYSA-N 0.000 claims abstract description 40
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 38
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 38
- 239000011669 selenium Substances 0.000 claims abstract description 38
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000011651 chromium Substances 0.000 claims abstract description 32
- 229910052804 chromium Inorganic materials 0.000 claims abstract description 32
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 27
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 27
- 241001327634 Agaricus blazei Species 0.000 claims abstract description 26
- 150000004676 glycans Chemical class 0.000 claims abstract description 26
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 26
- 239000005017 polysaccharide Substances 0.000 claims abstract description 26
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229940110767 coenzyme Q10 Drugs 0.000 claims abstract description 25
- 239000002775 capsule Substances 0.000 claims abstract description 11
- 239000000463 material Substances 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 26
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 12
- 238000002360 preparation method Methods 0.000 abstract description 10
- 206010028980 Neoplasm Diseases 0.000 abstract description 8
- 230000032683 aging Effects 0.000 abstract description 8
- 102000004877 Insulin Human genes 0.000 abstract description 6
- 108090001061 Insulin Proteins 0.000 abstract description 6
- 229940125396 insulin Drugs 0.000 abstract description 6
- 230000036039 immunity Effects 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 3
- 210000002216 heart Anatomy 0.000 abstract description 3
- 230000036772 blood pressure Effects 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 210000004185 liver Anatomy 0.000 abstract description 2
- 241000700605 Viruses Species 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 34
- 239000008280 blood Substances 0.000 description 34
- 229940091258 selenium supplement Drugs 0.000 description 33
- 235000000346 sugar Nutrition 0.000 description 27
- 239000000047 product Substances 0.000 description 24
- 241000282414 Homo sapiens Species 0.000 description 15
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 7
- 239000003925 fat Substances 0.000 description 7
- 229950006238 nadide Drugs 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 230000001603 reducing effect Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 201000001421 hyperglycemia Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000005515 coenzyme Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000003914 insulin secretion Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000033616 DNA repair Effects 0.000 description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000001800 adrenalinergic effect Effects 0.000 description 2
- 238000002266 amputation Methods 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 208000033679 diabetic kidney disease Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 208000005877 painful neuropathy Diseases 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 241001061264 Astragalus Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 229910021555 Chromium Chloride Inorganic materials 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000019926 Keshan disease Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 206010054805 Macroangiopathy Diseases 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 208000016222 Pancreatic disease Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010039921 Selenium deficiency Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 208000015606 cardiovascular system disease Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- VTNXYFSWTADICO-UHFFFAOYSA-N chromium 2-methylpyridine Chemical compound [Cr].CC1=NC=CC=C1 VTNXYFSWTADICO-UHFFFAOYSA-N 0.000 description 1
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000225 effect on diabetes Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 108091005995 glycated hemoglobin Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 235000020997 lean meat Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000004203 pancreatic function Effects 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Hematology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention provides a composition for treating diabetes, and belongs to the technical field of medicines. The invention comprises the following components in percentage by mass: 5 to 60 percent of beta-nicotinamide mononucleotide, 5 to 60 percent of chromium-enriched yeast, 5 to 60 percent of selenium-enriched yeast, 5 to 60 percent of agaricus blazei polysaccharide and 5 to 60 percent of coenzyme Q10. The preparation method comprises the following steps: mixing the above materials, and making into capsule or tablet. The composition for treating diabetes provided by the invention can activate insulin activity, treat and prevent various types of diabetes, prevent and assist in treating various tumors, inhibit viruses, improve the immunity of organisms, strengthen heart and liver, regulate blood pressure, keep young and shape, and delay aging.
Description
Technical Field
The invention relates to a composition for treating diabetes, and belongs to the technical field of medicines.
Background
Diabetes is a group of metabolic diseases characterized by hyperglycemia. Hyperglycemia is caused by a defect in insulin secretion or an impaired biological action, or both. The chronic hyperglycemia results in chronic damage and dysfunction of various tissues, particularly eyes, kidneys, heart, blood vessels and nerves.
Diabetes is prevalent worldwide and the number of patients is increasing dramatically. The prevalence rate of diabetes in China is increased from 0.67% in early 1980 to 9.7% in 2008, and the prevalence rate is increased by 13 times in nearly 30 years. According to the diabetes map published by International Diabetes Federation (IDF) in 2017, nearly 4.25 million people worldwide have diabetes in 2017, of which 80% are in mid-low income countries and one third are elderly people over 65 years old; if no positive action is taken, the number of diabetic patients in 2045 years will reach 6.29 billion. Wherein southeast Asia and western Tai district are serious areas of diabetes, and 1.21 hundred million diabetics exist in China. In adults over 18 years of age in our country, there are 1 diabetic patient per 10 and 1 pre-diabetic patient per 3. On one hand, the incidence of diabetes in China tends to be younger, and the diabetes in rural people is rapidly increased. On the other hand, the absolute number of diabetic patients continues to increase with the aging population and the life span of diabetic patients. Epidemiological survey results at home and abroad show that about one fourth of people over 60 years old suffer from diabetes; by age 80, the probability of diabetes can be as high as one-half. In addition, more huge people in the early stage of diabetes mellitus are provided, more than half of the middle-aged and the elderly in China have abnormal sugar metabolism, and the people are the people in diabetes mellitus or the people in the early stage of diabetes mellitus.
Diabetic complications are what cause disability and death and serious economic burden to diabetic patients. Very few of those with diabetes will actually die of severe hyperglycemia, and approximately two-thirds to three-quarters of those with diabetes will die of cardiovascular and cerebrovascular complications. Diabetes is the first cause of blindness in developed countries and is about the second cause in our country. One-third to forty percent of patients undergoing hemodialysis are due to diabetic nephropathy. According to our investigation, after removing malignant tumor in non-invasive amputation in large hospitals in China, about one half of the amputation is caused by diabetes. Diabetic neuropathy can cause multiple organ and tissue lesions, seriously reducing the quality of life of patients, and serious painful neuropathy can make patients feel undried. I have seen cases of diabetes suicided for severe painful neuropathy. Recent published investigations of large samples have shown that diabetics in our country die on average 7 years earlier than those without diabetes.
At present, no safe and definite diabetes product which can be adjusted from a whole body system to a healthy state to recover the functions of the pancreatic islets and finally replace injected insulin and oral hypoglycemic drugs exists all over the world.
Research and development of safe, healthy and effective revolutionary products for diabetes mellitus are the leading directions of research of new drugs and are urgent demands of the sick population all over the world.
Disclosure of Invention
The present invention has been made to solve the above-mentioned problems occurring in the prior art, and an object of the present invention is to provide a composition for treating diabetes.
The purpose of the invention is realized by the following technical scheme:
the composition for treating diabetes comprises the following components in percentage by mass: 5 to 60 percent of NMN (beta-nicotinamide mononucleotide), 5 to 60 percent of chromium-enriched yeast, 5 to 60 percent of selenium-enriched yeast, 5 to 60 percent of agaricus blazei polysaccharide and 5 to 60 percent of coenzyme Q10.
Preferably, the composition comprises the following components in percentage by mass: 5 to 50 percent of NMN (beta-nicotinamide mononucleotide), 5 to 50 percent of chromium-enriched yeast, 5 to 50 percent of selenium-enriched yeast, 5 to 50 percent of agaricus blazei polysaccharide and 5 to 50 percent of coenzyme Q10.
Preferably, the composition comprises the following components in percentage by mass: 5 to 45 percent of NMN (beta-nicotinamide mononucleotide), 5 to 45 percent of chromium-enriched yeast, 5 to 45 percent of selenium-enriched yeast, 5 to 45 percent of agaricus blazei polysaccharide and 5 to 45 percent of coenzyme Q10.
Preferably, the composition comprises the following components in percentage by mass: 15% of NMN (beta-nicotinamide mononucleotide), 25% of chromium-rich yeast, 25% of selenium-rich yeast, 25% of agaricus blazei polysaccharide and 10% of coenzyme Q10.
Preferably, the composition comprises the following components in percentage by mass: 20% of NMN (beta-nicotinamide mononucleotide), 20% of chromium-rich yeast, 20% of selenium-rich yeast, 20% of agaricus blazei polysaccharide and 20% of coenzyme Q10.
Preferably, the composition comprises the following components in percentage by mass: 15% of NMN (beta-nicotinamide mononucleotide), 35% of chromium-rich yeast, 15% of selenium-rich yeast, 25% of agaricus blazei polysaccharide and 10% of coenzyme Q10.
Preferably, the composition comprises the following components in percentage by mass: 10% of NMN (beta-nicotinamide mononucleotide), 35% of chromium-rich yeast, 15% of selenium-rich yeast, 25% of agaricus blazei polysaccharide and 15% of coenzyme Q10.
The invention also provides a preparation method of the diabetes treatment product, which comprises the following steps: mixing the above materials, and making into capsule or tablet.
Preferably, the weight of the capsule is 0.45-0.55 g.
The invention has the beneficial effects that:
the invention provides a composition for treating diabetes and a preparation method thereof, wherein the composition comprises the following components in percentage by mass: 5 to 60 percent of NMN (beta-nicotinamide mononucleotide), 5 to 60 percent of chromium-rich yeast, 5 to 60 percent of selenium-rich yeast, 5 to 60 percent of agaricus blazei polysaccharide and 105 to 60 percent of coenzyme Q.
The composition I is as follows: NMN (beta-nicotinamide mononucleotide)
NMN is an abbreviation for β -nicotinamide mononucleotide, occurs naturally in living cells, and is a precursor of coenzyme 1NAD + (nicotinamide adenine dinucleotide). The life can be properly prolonged. What really plays an anti-aging role is an important energy metabolite called nicotinamide adenine dinucleotide (NAD +).
With age, a decrease in NAD + levels leads to a decrease in DNA repair capacity, accumulation of DNA damage, driving the aging process. NAD + participates in cellular respiration and promotes energy metabolism (e.g., oxidation of glucose, fats, amino acids). NAD + is not only a coenzyme for hundreds of redox reactions in living cells, but it is also involved as a substrate in regulating various physiological functions such as cell survival, apoptosis, DNA repair, immune response, circadian rhythm, and the like.
NMN is a nutrient that is converted to NAD + in cells, is classified as a novel vitamin B3, and surpasses the efficacy of common vitamins, and is considered as a supplement for preventing aging and restoring youth. Since their discovery in 1906, NAD + has received scientific attention due to its abundance in the human body and its key role in the molecular pathways that maintain human functioning. In animal studies, increasing the level of NAD + in vivo has shown encouraging results in the areas of research such as metabolism and age-related diseases, and even certain anti-aging properties. Age-related diseases such as diabetes, cardiovascular disease, neurodegeneration and a general decline of the immune system.
And (2) component two: chromium-rich yeast
The natural blood sugar regulator has the functions of activating insulin activity, regulating blood sugar and inhibiting the conversion of sugar into fat.
The main function of chromium-rich yeast
Enhance insulin activity and control blood sugar. Can regulate fat storage amount and help reduce weight. Reducing blood cholesterol and triglyceride content, and preventing cardiovascular diseases. It has the main functions as follows:
1. reducing blood sugar of diabetic patients, improving hypoglycemia reaction, regulating blood sugar, controlling diabetes effectively, and eliminating abnormal phenomena of glucose tolerance.
2. Can obviously reduce serum cholesterol level of the calluses and relieve arteriosclerosis symptoms.
3. Can be used for correcting abnormal sugar tolerance of children with chromium deficiency and patients with long-term parenteral nutrition.
4. Can effectively increase human muscle and reduce fat.
5. The addition of chromium to the growing/finishing pig ration can significantly improve carcass lean meat percentage, improve feed conversion rate, reduce back fat thickness, and improve breeding performance of sows and survival rate of piglets.
6. Can increase laying rate of laying hens, reduce egg cholesterol, increase growth speed of broiler chickens, and reduce fat content of breast muscle.
7. Can improve animal endocrine and enhance anti-stress capability.
The chromium-rich yeast has the advantages that:
1. toxicity tests prove that the yeast chromium is safe to eat and has no toxicity.
2. The yeast chromium contains bioactive chromium with high human body absorptivity, wherein the absorptivity is 311% of methylpyridine chromium and 672% of chromium chloride.
3. The yeast chromium is rich in protein, sugar and B vitamins, and can be used as a chromium source and also provide other beneficial nutrients.
4. The yeast chromium can be industrially produced in a large scale, has low production and taking cost and is easy to popularize.
The composition III: selenium-enriched yeast
Selenium-enriched yeast is added with selenium element in the process of culturing yeast, and the selenium is absorbed and utilized during the growth of the yeast, so that the selenium is organically combined with protein and polysaccharide in the yeast body and converted into biological selenium, thereby eliminating the toxic and side reaction and the gastrointestinal stimulation of chemical selenium (such as sodium selenite) to a human body, and enabling the selenium to be absorbed and utilized by the human body more efficiently and more safely. The selenium-enriched yeast is the most efficient, safest and balanced nutritional selenium supplement preparation at home so far. Selenium is a trace element necessary for human bodies, has important physiological functions and is closely related to the health of human beings. Selenium can prevent and inhibit tumor, resist aging, maintain normal function of cardiovascular system, and prevent arteriosclerosis and coronary heart disease. Selenium deficiency can cause keshan disease and large bone disease, and can also induce cataract, liver disease, pancreatic disease, etc. Selenium stimulates the production of immunoglobulins and enables various immune functions of the human body such as: cellular immunity, humoral immunity, non-specificity, etc. are improved. The blood selenium of the diabetics is obviously lower than that of normal people. Selenium supplement can lower blood glucose level and increase GPX activity. Selenium has insulin-like action and can stimulate transport of glucan carrier in fat cell membrane. The glutathione peroxidase activity in the body of a diabetic is at an extremely low level, the activity is lower as the disease time is longer, and the selenium-rich yeast is taken regularly, so that the effects of protecting and recovering pancreas functions can be achieved, the metabolic regulation of the diabetes mellitus can be improved, and the level of the glucosylated hemoglobin in urine can be reduced. Therefore, the selenium-enriched yeast is a very ideal functional food base material, and has a very wide development prospect, just as the authoritative doctor fieldry of trace elements in the world: "selenium is like an atomic bomb, the quantity is very small, the action and power are very large, once recognized, it will have profound effect on health".
The component IV is as follows: agaricus blazei Murill polysaccharide
The Agaricus blazei Murill polysaccharide is effective active ingredient extracted from high-quality Agaricus blazei Murill fruiting body, has fragrant smell, remarkable effect, and effects of enhancing energy, inhibiting growth of tumor cells, resisting tumor, and absorbing and eliminating carcinogenic substances. It also has effects in lowering blood sugar, improving diabetes, reducing cholesterol, and improving arteriosclerosis. The pharmacological actions thereof have been confirmed mainly as follows: anti-tumor effect, immunoregulation effect, cell repairing effect, and acid-base balance regulation. The agaricus blazei polysaccharide has wide food therapy and clinical symptom improvement range. Not only has obvious effects on enhancing immunity, preventing cancer and resisting cancer, but also has obvious effects on hypertension, thrombus, arteriosclerosis and the like of a circulatory system; for gastritis, gastric ulcer, hepatomegaly, enteritis, renal insufficiency, etc. of digestive system; diabetes, allergy, high cholesterol, etc. to the endocrine system; has certain dietotherapy effect and symptom improving effect on bought bronchitis, asthma and the like of a respiratory system, gynecological diseases of a reproductive system, climacteric syndrome and the like. Agaricus blazei polysaccharide has been used in Japan for treating 4 cases of cancer, 2 cases of diabetes, 3 cases of hemorrhoid, 1 case of neuralgia, 3 cases of tinea pedis, and 1 case of liver disease, and enhancing many cases of physical quality. The clinical observation of China proves that the Chinese medicinal composition has certain curative effect on diabetes, digestive tract tumor and chronic hepatitis.
The fifth component: coenzyme Q10
Coenzyme Q10 is a fat-soluble antioxidant, coenzyme Q10 is one of essential important elements for human life, can activate the nutrition of human cells and cell energy, has the functions of improving human immunity, enhancing antioxidation, delaying senility, enhancing human vitality and the like, and is widely used for cardiovascular system diseases in medicine. The main functions are as follows:
1. coenzyme Q10 is used as a strong antioxidant alone or in combination with vitamin B6 (pyridoxine), and can inhibit the modification of free radicals on microtubule system of immune cell receptor related to cell differentiation and activity, enhance immune system, and delay aging.
2. Coenzyme Q10 helps to provide sufficient oxygen to the heart muscle and prevent sudden heart disease, and coenzyme Q10 plays a key role especially during myocardial hypoxia.
3. The coenzyme Q10 can accelerate fat metabolism, and make energy supply of limbs and brain abundant and energy invigorating.
4. Can be used as skin care product for improving skin elasticity.
The scientific combination of the components improves the functions of human organs, enhances the immunity of the organism, emphasizes on recovering the function of pancreatic islets, accurately treats various types of diabetes, considers the treatment and maintenance of complications and the treatment of tumors, strengthens the heart, nourishes the liver, regulates the blood pressure, beautifies and builds up the body, and delays aging from the whole and the root of the organism.
The invention realizes the all-around improvement of the disease resistance of each organ through scientific proportioning and makes up for the defect of single component. Not only improves the aging speed of human cells from the perspective of gene, but also weakens the degradation of system function from the perspective of supplementing necessary micro-amount for human body, and simultaneously stimulates the vitality and the anti-cancer variable ability of human body from the perspective of immunity. Through the scientific compatibility, the functions of all the components are brought into full play, and simultaneously, more beneficial comprehensive effects are generated.
Secondly, through the synergistic compatibility, the fundamental problem of diabetes is accurately, efficiently and safely solved, the origin is really activated, and both principal and secondary aspects of diseases are treated. Because the project focuses on restoring the system at first and then restoring the islet function at first, the diabetes mellitus is treated by the project not only by the surface phenomenon of blood sugar data, but also by the project which stands for a long time, the islet function is completely restored, the mechanism of relevant visceral organs entering virtuous cycle is promoted, the defects of blood sugar rebound, drug dependence and the like are effectively avoided, and a safer and healthier blood sugar reducing product is created.
Detailed Description
The invention will be described in further detail below with reference to the accompanying drawings: the present embodiment is implemented on the premise of the technical solution of the present invention, and a detailed embodiment is given, but the scope of the present invention is not limited to the following embodiments.
The present embodiment relates to a composition for treating diabetes, comprising:
the invention provides a composition for treating diabetes and a preparation method thereof, wherein the composition comprises the following components in percentage by mass: 5 to 60 percent of NMN (beta-nicotinamide mononucleotide), 5 to 60 percent of chromium-rich yeast, 5 to 60 percent of selenium-rich yeast, 5 to 60 percent of agaricus blazei polysaccharide and 105 to 60 percent of coenzyme Q.
In the present invention, the diabetes treatment product includes 5% to 60% by mass of NMN (β -nicotinamide mononucleotide), more preferably 5% to 45%, and still more preferably 10%.
In the present invention, the diabetes treatment product includes 5 to 60 mass% of chromium-rich yeast, more preferably 35 mass%, and still more preferably 10 mass%.
In the invention, the diabetes treatment product comprises 5-60% of selenium-enriched yeast by mass, more preferably 5-45%, and even more preferably 15%.
In the present invention, the diabetes treatment product includes 5 to 60 mass% of agaricus blazei murrill polysaccharide, more preferably 5 to 45 mass%, and still more preferably 25 mass%.
In the present invention, the diabetes treatment product includes 5% to 60% by mass of coenzyme Q10, more preferably 5% to 45%, and still more preferably 15%.
The diabetes treatment product provided by the invention is taken orally, and only needs to be taken once every day, 2 granules each time. One month is a treatment course.
The invention also provides a preparation method of the diabetes treatment product, which comprises the following steps: mixing the above materials, and making into capsule or tablet.
Example 1
A composition for treating diabetes comprises the following components in parts by mass:
150g of NMN (beta-nicotinamide mononucleotide), 250g of chromium-enriched yeast, 250g of selenium-enriched yeast, 250g of agaricus blazei murrill polysaccharide and 100g of coenzyme Q10. The raw materials are purchased from domestic production enterprises meeting the standards and specifications of the product industry. 1000g of the product is prepared, and 2000 grains of the product are prepared.
The preparation method comprises the following steps: mixing the above materials, and making into capsule or tablet.
Example 2
A composition for treating diabetes comprises the following components in parts by mass:
200g of NMN (beta-nicotinamide mononucleotide), 200g of chromium-enriched yeast, 200g of selenium-enriched yeast, 200g of agaricus blazei murill polysaccharide and 200g of coenzyme Q10. The raw materials are purchased from domestic production enterprises meeting the standards and specifications of the product industry. 1000g of the product is prepared, and 2000 grains of the product are prepared.
The source of the raw materials and the preparation method are the same as those of example 1.
Example 3
A composition for treating diabetes comprises the following components in parts by mass:
150g of NMN (beta-nicotinamide mononucleotide), 350g of chromium-enriched yeast, 150g of selenium-enriched yeast, 250g of agaricus blazei murrill polysaccharide and 100g of coenzyme Q10. The raw materials are purchased from domestic production enterprises meeting the standards and specifications of the product industry. 1000g of the product is prepared, and 2000 grains of the product are prepared.
The source of the raw materials and the preparation method are the same as those of example 1.
Example 4
A composition for treating diabetes comprises the following components in parts by mass:
100g of NMN (beta-nicotinamide mononucleotide), 350g of chromium-enriched yeast, 150g of selenium-enriched yeast, 250g of agaricus blazei murill polysaccharide and coenzyme Q10150 g. The raw materials are purchased from domestic production enterprises which meet the standards and specifications of the product industry. 1000g of the product is prepared, and 2000 grains of the product are prepared.
The source of the raw materials and the preparation method are the same as those of example 1.
Examples of the experiments
The pharmacodynamic test result of the invention is as follows:
in the experiment, 60 healthy rats are randomly divided into 6 groups which are respectively blank control groups, a small, medium and large dose (0.17, 0.5 and 1.5g/kg) group of a composition for treating diabetes mellitus, a 0.5g/kg group of ginseng and astragalus blood-glucose-reducing capsules and a 0.075g/kg group of a composition for treating diabetes mellitus are filled into the stomach according to the volume of 1ml/100g of body weight, the blank group is filled with distilled water with the same volume once a day and continuously for 15d, the fasting is not forbidden for 12h before the last administration, the fasting is not forbidden for 15h after the last administration, the ip adrenaline is 0.5mg/kg in each group, the glucose solution is filled into the stomach at the dose of 1g/kg, the model is accelerated, and the fasting blood glucose changes of 1h, 2h and 3h after the model is respectively measured. The blood is collected by cutting the tail, and the blood sugar content of the serum is measured by a glucose oxidase method.
Table 1 effect of a composition for treating diabetes on adrenergic hyperglycemic rat levels (n-10)
)
Note that t-tests were performed between groups, P < 005 and P < 001 compared to the blank control group.
Table 2 effect of a composition capsule for treating diabetes on blood sugar, blood lipid, SOD, MAD, insulin levels in alloxan type diabetic rats (n-8)
)
Note that the t test between groups compares the delta P with the model control group to be less than 005 and the delta P with the model control group to be less than 001; model control group compared with blank control group # # P < 001.
Table 3 effect of a composition capsule for treating diabetes on normal mouse blood glucose (n-10)
)
TABLE 4 glucose tolerance of a composition capsule for the treatment of diabetesInfluence (n ═ 10)
)
The pharmacodynamic test result of the project shows that: (see tables 1-4)
1. The invention can reduce the blood sugar level of the rat with the adrenergic hyperglycemia.
2. After the rat model building of the diabetes mellitus by the alloxan, the blood sugar is increased, the serum insulin level is reduced, the generation of in vivo free radicals is increased, the MDA content is increased, the SOD content is reduced, and the triglyceride and cholesterol content is increased. A composition for treating diabetes can obviously inhibit the change, protect insulin secretion, reduce MDA content and improve SOD activity, has obvious statistical significance compared with a model group, and has the effects of resisting oxidation, reducing blood sugar and increasing insulin secretion which are stronger than the blood fat reducing effect.
3. The invention has no obvious influence on the blood sugar of normal mice.
4. The glucose tolerance of the invention has no obvious influence.
The clinical observation statistical table of the invention is as follows:
TABLE 5 comparison of the therapeutic effects of the treated groups with those of the control group
％
| Group of | n | Display efficiency | High efficiency | Inefficiency of | Total effective rate |
| Treatment group | 180 | 44.0 | 43.3 | 14.7 | 87.3 |
| Control group | 180 | 24.5 | 19.6 | 45.9 | 44.1 |
P < 005 compared to control.
The evaluation standard of curative effect is as follows: the effect is shown: three more and one less and other symptoms disappear, the body has no discomfort, the FBG is within 6.1mmol/L, and the blood sugar (PBG) after 2 hours of meal is within 7.2 mmol/L; the method has the following advantages: three more or one less and other symptoms are obviously relieved, the blood sugar of 2 hours after the meal and the fasting blood sugar are obviously reduced than the original blood sugar or the fasting blood sugar is reduced to 8 mmol/L-10 mmol/L, and the blood sugar of 2 hours after the meal is reduced to 10 mmol/L-13 mmol/L; and (4) invalidation: "three more and one less" and other symptoms are not improved, and the blood sugar is not obviously reduced or changed.
TABLE 6 two sets of FBG, PBG and HbAlC changes
Compared with the group before treatment, # P < 0.05; p <0.05 after treatment compared to control group
TABLE 7 blood lipid changes in two groups
Compared with the group before treatment, # P < 0.05; p <0.05 after treatment compared to control group
Clinical trials of this project showed that: (see tables 5-7)
Clinical study the clinical efficacy of the composition for treating type 2 diabetes was verified by observing the changes in clinical symptoms, blood glucose, glycated hemoglobin, blood lipids, etc., before and after treatment of 360 patients with diabetes by using one composition for treating diabetes. 360 patients with type 2 diabetes mellitus of last five years at home and abroad, 192 men and 168 women, and the age of 35-80 years; the disease course of diabetes is 2 to 28 years; 168 cases of combined macroangiopathy (144 cases of hypertension, 18 cases of cerebral infarction and 12 cases of diabetic heart disease) and 180 cases of microangiopathy (36 cases of diabetic retinopathy, 33 cases of diabetic nephropathy and 117 cases of peripheral neuropathy).
The research finds that the total effective rate of the composition for treating diabetes mellitus is 86.3 percent and is superior to that of a control group. The blood sugar and the glycosylated hemoglobin of the treatment group are obviously improved before and after treatment; the triacylglycerol, cholesterol and low-density lipoprotein cholesterol were significantly reduced and the high-density lipoprotein cholesterol was increased before and after treatment in the two groups, and the treatment group and the control group had statistical significance.
The above description is only a preferred embodiment of the present invention, and these embodiments are based on different implementations of the present invention, and the scope of the present invention is not limited thereto, and any changes or substitutions that can be easily conceived by those skilled in the art within the technical scope of the present invention are included in the scope of the present invention. Therefore, the protection scope of the present invention shall be subject to the protection scope of the claims.
Claims (8)
1. The composition for treating diabetes is characterized by comprising the following components in percentage by mass: 5 to 60 percent of beta-nicotinamide mononucleotide, 5 to 60 percent of chromium-enriched yeast, 5 to 60 percent of selenium-enriched yeast, 5 to 60 percent of agaricus blazei polysaccharide and 5 to 60 percent of coenzyme Q10.
2. The composition for treating diabetes according to claim 1, which comprises the following components in percentage by mass: 5 to 50 percent of beta-nicotinamide mononucleotide, 5 to 50 percent of chromium-enriched yeast, 5 to 50 percent of selenium-enriched yeast, 5 to 50 percent of agaricus blazei polysaccharide and 5 to 50 percent of coenzyme Q10.
3. The composition for treating diabetes according to claim 1, which comprises the following components in percentage by mass: 5 to 45 percent of beta-nicotinamide mononucleotide, 5 to 45 percent of chromium-enriched yeast, 5 to 45 percent of selenium-enriched yeast, 5 to 45 percent of agaricus blazei polysaccharide and 5 to 45 percent of coenzyme Q10.
4. The composition for treating diabetes according to claim 1, which comprises the following components in percentage by mass: 15% of beta-nicotinamide mononucleotide, 25% of chromium-enriched yeast, 25% of selenium-enriched yeast, 25% of agaricus blazei polysaccharide and 10% of coenzyme Q10.
5. The composition for treating diabetes according to claim 1, which comprises the following components in percentage by mass: 20% of beta-nicotinamide mononucleotide, 20% of chromium-enriched yeast, 20% of selenium-enriched yeast, 20% of agaricus blazei polysaccharide and 20% of coenzyme Q10.
6. The composition for treating diabetes according to claim 1, which comprises the following components in percentage by mass: 15% of beta-nicotinamide mononucleotide, 35% of chromium-enriched yeast, 15% of selenium-enriched yeast, 25% of agaricus blazei polysaccharide and 10% of coenzyme Q10.
7. The method for preparing a composition for treating diabetes according to any one of claims 1 to 6, comprising the steps of: mixing the above materials, and making into capsule or tablet.
8. The method of claim 7, wherein the capsule has a weight of 0.45 to 0.55 g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110012077.0A CN114028434A (en) | 2021-01-06 | 2021-01-06 | A composition for treating diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110012077.0A CN114028434A (en) | 2021-01-06 | 2021-01-06 | A composition for treating diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114028434A true CN114028434A (en) | 2022-02-11 |
Family
ID=80139707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110012077.0A Pending CN114028434A (en) | 2021-01-06 | 2021-01-06 | A composition for treating diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114028434A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040234513A1 (en) * | 2003-05-19 | 2004-11-25 | Cross Bay, Llc | Composition and method for reducing blood glucose |
| US20080268066A1 (en) * | 2005-03-30 | 2008-10-30 | Pficker Pharmaceuticals Ltd. | Synergistic Formulation for Preventing and/or Treating Diabetes |
| CN101658537A (en) * | 2008-08-27 | 2010-03-03 | 安琪酵母股份有限公司 | Hypoglycemic ferment compound |
| JP2018203691A (en) * | 2017-06-08 | 2018-12-27 | 興人ライフサイエンス株式会社 | Diabetes improving agent or preventive agent |
-
2021
- 2021-01-06 CN CN202110012077.0A patent/CN114028434A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040234513A1 (en) * | 2003-05-19 | 2004-11-25 | Cross Bay, Llc | Composition and method for reducing blood glucose |
| US20080268066A1 (en) * | 2005-03-30 | 2008-10-30 | Pficker Pharmaceuticals Ltd. | Synergistic Formulation for Preventing and/or Treating Diabetes |
| CN101658537A (en) * | 2008-08-27 | 2010-03-03 | 安琪酵母股份有限公司 | Hypoglycemic ferment compound |
| JP2018203691A (en) * | 2017-06-08 | 2018-12-27 | 興人ライフサイエンス株式会社 | Diabetes improving agent or preventive agent |
Non-Patent Citations (2)
| Title |
|---|
| 张颖: "β-烟酰胺单核苷酸合成技术研究进展", 《食品科技》 * |
| 言挺等: "铬的生物学作用及富铬酵母在糖尿病治疗中的应用", 《微量元素与健康研究》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101624570B (en) | Method for cultivating cultured ganoderma lucidum with Chinese medicaments and method for preparing cultured ganoderma lucidum health-care product | |
| CN101574140B (en) | Drink composition with human immunity strengthening and anti-fatigue functions | |
| CN111011691A (en) | High-protein high-fiber solid beverage | |
| CN103431392B (en) | Composite marine food for special dietary uses for diabetics | |
| CN103637197A (en) | Propolis soft capsule and preparation method thereof | |
| CN102526478B (en) | Formula of health-care medicine with functions of strengthening immunity and reducing blood sugar | |
| CN106107463A (en) | Super Quinoa Antifatigue milk tea processing technology | |
| CN106806643A (en) | A kind of Chinese medicine composition for treating diabetes | |
| CN1814167A (en) | Health-care for diabetes | |
| CN104543834A (en) | Pumpkin powder with blood sugar reducing effect and preparation method thereof | |
| CN105768108A (en) | Special dietary food suitable for taking of tumor patients | |
| CN105533688A (en) | Healthcare soft capsule with assistant blood-sugar reducing effect and preparation method thereof | |
| CN107279296A (en) | A kind of formula food of suitable diabetes and preparation method thereof | |
| CN109939143A (en) | A kind of Chinese medicine composition and preparation method thereof for hypoglycemic control complication | |
| CN102613453B (en) | Marine organism type enteral nutrition preparation for diabetes patients, preparation method of marine organism type enteral nutrition preparation and application | |
| CN101664180B (en) | Health-care nutritional complexing agent with health effect and preparation method thereof | |
| CN105613882A (en) | Black barley hypoglycemic tea (milky tea) | |
| CN108244654A (en) | Caterpillar fungus nutritire breakfast flour | |
| CN103404875B (en) | Complex ocean special-diet food eaten by patients with cardiovascular disease | |
| CN102631466A (en) | Health care product for regulating blood lipid and preparation method thereof | |
| CN108371709A (en) | Lycium ruthenicum tumor recovering gene enzyme | |
| CN114028434A (en) | A composition for treating diabetes | |
| CN115005436A (en) | White kidney bean fermentation extract, preparation method thereof and application of white kidney bean fermentation extract in reducing blood sugar and blood pressure | |
| CN102823778A (en) | Functional feed additive special for experimental miniature pig | |
| CN106035686A (en) | Super chenopodium quinoa willd health-preservation plant milk |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220211 |
|
| RJ01 | Rejection of invention patent application after publication |